Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma

Jiang,Ning; Liu,Na; Yang,Fan; Zhou,Qiming; Cui,Ruixue; Jiang,Wei; He,Qingmei; Li,Wenfei; Guo,Ying; Zeng,Jing; Yun,Jingping; Chen,Xinchun; Zhou,Boping; Sun,Ying; Wang,Huiyun; Chen,Zhuo  G.; Ma,Jun

doi:10.3892/or.2014.3376

Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma

Authors:
- Ning Jiang
- Na Liu
- Fan Yang
- Qiming Zhou
- Ruixue Cui
- Wei Jiang
- Qingmei He
- Wenfei Li
- Ying Guo
- Jing Zeng
- Jingping Yun
- Xinchun Chen
- Boping Zhou
- Ying Sun
- Huiyun Wang
- Zhuo G. Chen
- Jun Ma
View Affiliations

Affiliations: State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, Shenzhen Institute of Liver Diseases, The Third People's Hospital, Shenzhen, Guangdong 518112, P.R. China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, National Clinical Study Center for Anticancer Drugs, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA
Published online on: August 1, 2014 https://doi.org/10.3892/or.2014.3376
Pages: 1661-1669

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oncogene mutations contribute to carcinogenesis and can provide potential therapeutic targets for clinical anticancer management. However, oncogene mutation patterns in nasopharyngeal carcinoma (NPC) have yet to be fully elucidated. To gain insight into mutation patterns in NPC, a high-throughput OncoCarta panel assay was used to determine 238 hotspot mutations across 19 common oncogenes in 8 NPC cell lines and 160 NPC patient samples from southern China. Statistical analyses were further conducted to identify associations between oncogene mutations and selected clinicopathological characteristics. In total, we identified 24 mutations across 11 oncogenes in 17 (10.6%) NPC patients. Four patients exhibited mutations in at least one oncogene. We also identified a PIK3CA H1047R mutant in 7 NPC cell lines. In addition, oncogene mutations showed no correlation with either risk habits (smoking and drinking) or other clinical characteristics except for TNM stage. KIT mutations were associated with poorer overall and relapse-free survival. Furthermore, KIT mutations together with age and N stage were independent prognostic factors in NPC. Taken together, the present study is the first report on mutations in multiple oncogenes in NPC. We found that hotspot oncogene mutations are infrequent in NPC patients from southern China. The lack of hotspot mutations requires a comprehensive characterization of gene mutations in NPC for developing new therapeutic targets in the future.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Lee AW, Sze WM, Au JS, et al: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys. 61:1107–1116. 2005. View Article : Google Scholar : PubMed/NCBI
3	Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 23:6730–6738. 2005. View Article : Google Scholar
4	Bensouda Y, Kaikani W, Ahbeddou N, et al: Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 128:79–85. 2011. View Article : Google Scholar : PubMed/NCBI
5	Caponigro F, Longo F, Ionna F and Perri F: Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs. 21:471–477. 2010. View Article : Google Scholar : PubMed/NCBI
6	Ma BB and Chan AT: Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther. 6:383–394. 2006. View Article : Google Scholar : PubMed/NCBI
7	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
8	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
9	Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 27:4247–4253. 2009. View Article : Google Scholar : PubMed/NCBI
10	Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 486:532–536. 2012.PubMed/NCBI
11	Bardelli A and Janne PA: The road to resistance: EGFR mutation and cetuximab. Nat Med. 18:199–200. 2012. View Article : Google Scholar : PubMed/NCBI
12	Klein G: Nasopharyngeal carcinoma (NPC) is an enigmatic tumor. Semin Cancer Biol. 12:415–418. 2002.PubMed/NCBI
13	Hui AB, Lo KW, Leung SF, et al: Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer. 82:498–503. 1999. View Article : Google Scholar : PubMed/NCBI
14	Fan CS, Wong N, Leung SF, et al: Frequent c-myc and Int-2 over-representations in nasopharyngeal carcinoma. Hum Pathol. 31:169–178. 2000. View Article : Google Scholar : PubMed/NCBI
15	Hui AB, Lo KW, Teo PM, To KF and Huang DP: Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol. 20:467–473. 2002.PubMed/NCBI
16	Forbes SA BG, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA and Stratton MR: The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. Chapter 10:2008.
17	Chou CC, Chou MJ and Tzen CY: PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol. 26:322–326. 2009. View Article : Google Scholar : PubMed/NCBI
18	Yip WK, Leong VC, Abdullah MA, Yusoff S and Seow HF: Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep. 19:319–328. 2008.PubMed/NCBI
19	Fendri A, Khabir A, Mnejja W, et al: PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci. 100:2034–2039. 2009. View Article : Google Scholar : PubMed/NCBI
20	Naji F, Attaleb M, Laantri N, et al: Identification of G2607A mutation in EGFR gene with a significative rate in Moroccan patients with nasopharyngeal carcinoma. Cell Mol Biol. 56:OL1442–OL1446. 2010.PubMed/NCBI
21	Huang PY, Hong MH, Zhang X, Mai HQ, Luo DH and Zhang L: C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines. Chin J Cancer. 29:131–135. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
23	Fumagalli D, Gavin PG, Taniyama Y, et al: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 10:1012010. View Article : Google Scholar : PubMed/NCBI
24	Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011. View Article : Google Scholar : PubMed/NCBI
25	Liu N, Tang LL, Sun Y, et al: MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 329:181–188. 2013. View Article : Google Scholar : PubMed/NCBI
26	Wetterskog D, Lopez-Garcia MA, Lambros MB, et al: Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol. 226:84–96. 2012. View Article : Google Scholar : PubMed/NCBI
27	Duprez R, Wilkerson PM, Lacroix-Triki M, et al: Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol. 226:427–441. 2012. View Article : Google Scholar : PubMed/NCBI
28	Thomas RK, Baker AC, Debiasi RM, et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet. 39:347–351. 2007. View Article : Google Scholar : PubMed/NCBI
29	Pearce M, Hogg G, Hosseni D and Ehrich M: Mutation profiling in tumor samples using the Sequenom OncoCarta™ Panel. Nature Methods. 6:vii–viii. 2009.
30	Jhawer M, Goel S, Wilson AJ, et al: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 68:1953–1961. 2008. View Article : Google Scholar : PubMed/NCBI
31	Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncology. 11:521–529. 2010. View Article : Google Scholar : PubMed/NCBI
32	Tie J, Lipton L, Desai J, et al: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 17:1122–1130. 2011. View Article : Google Scholar : PubMed/NCBI
33	Or YY, Hui AB, To KF, Lam CN and Lo KW: PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer. 118:1065–1067. 2006. View Article : Google Scholar : PubMed/NCBI
34	Qian CN, Guo X, Cao B, et al: Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res. 62:589–596. 2002.PubMed/NCBI
35	Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39:D945–D950. 2011. View Article : Google Scholar : PubMed/NCBI
36	Su KY, Chen HY, Li KC, et al: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440. 2012. View Article : Google Scholar : PubMed/NCBI
37	Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 21:99–102. 1999. View Article : Google Scholar : PubMed/NCBI
38	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
39	Kang S, Bader AG and Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA. 102:802–807. 2005. View Article : Google Scholar : PubMed/NCBI
40	Abers GA, Ferris A, Craig M, et al: Mantle compensation of active metamorphic core complexes at Woodlark rift in Papua New Guinea. Nature. 418:862–865. 2002. View Article : Google Scholar : PubMed/NCBI
41	Qiu FH, Ray P, Brown K, et al: Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J. 7:1003–1011. 1988.PubMed/NCBI
42	Phung B, Sun J, Schepsky A, Steingrimsson E and Ronnstrand L: C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One. 6:e240642011. View Article : Google Scholar : PubMed/NCBI
43	Orfao A, Garcia-Montero AC, Sanchez L and Escribano L; REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol. 138:12–30. 2007. View Article : Google Scholar : PubMed/NCBI
44	Nakagomi N and Hirota S: Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest. 87:365–371. 2007.PubMed/NCBI
45	Longley BJ Jr, Metcalfe DD, Tharp M, et al: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA. 96:1609–1614. 1999. View Article : Google Scholar : PubMed/NCBI
46	Growney JD, Clark JJ, Adelsperger J, et al: Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood. 106:721–724. 2005. View Article : Google Scholar : PubMed/NCBI
47	Lennartsson J and Rönnstrand L: Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 92:1619–1649. 2012. View Article : Google Scholar : PubMed/NCBI
48	Ma BB, Lui VW, Poon FF, et al: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs. 28:326–333. 2010. View Article : Google Scholar : PubMed/NCBI
49	Yasuda H, Kobayashi S and Costa DB: EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 13:e23–e31. 2012. View Article : Google Scholar : PubMed/NCBI
50	Rane SG, Cosenza SC, Mettus RV and Reddy EP: Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol. 22:644–656. 2002. View Article : Google Scholar : PubMed/NCBI
51	Vax VV, Bibi R, Diaz-Cano S, et al: Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. J Endocrinol. 178:301–310. 2003. View Article : Google Scholar : PubMed/NCBI
52	Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62:6997–7000. 2002.PubMed/NCBI
53	Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
54	Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
55	Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI